Ascentage Net Income From Continuing Ops from 2010 to 2026
| AAPG Stock | 22.77 -1.23 -5.13% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -466.5 M | Current Value -489.9 M | Quarterly Volatility 129.3 M |
Ascentage | Net Income From Continuing Ops | Build AI portfolio with Ascentage Stock |
Latest Ascentage Pharma's Net Income From Continuing Ops Growth Pattern
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Ascentage Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | -670,988,035 | |
| Coefficient Of Variation | -19.28 | |
| Mean Deviation | 76,575,707 | |
| Median | -677,606,000 | |
| Standard Deviation | 129,349,187 | |
| Sample Variance | 16731.2T | |
| Range | 520M | |
| R-Value | 0.21 | |
| Mean Square Error | 17030.6T | |
| R-Squared | 0.05 | |
| Significance | 0.41 | |
| Slope | 5,477,444 | |
| Total Sum of Squares | 267699.4T |
Ascentage Net Income From Continuing Ops History
Stock Overview, Methodology & Data Sources
Methodology
Unless otherwise specified, financial data for Ascentage Pharma Group is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Ascentage (USA Stocks:AAPG) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Ascentage Pharma Group is covered by 7 analysts. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include J.P. Morgan, Stifel, BMO Capital Markets, Oppenheimer & Co., Citigroup, RBC Capital Markets, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardCurrently Active Assets on Macroaxis
More Resources for Ascentage Stock Analysis
Reviewing Ascentage Pharma commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for Ascentage Pharma Group Stock. Below are reports that help frame Ascentage Pharma Group Stock in context: Earnings Share -2.10 | Revenue Per Share | Quarterly Revenue Growth -0.72 | Return On Assets | Return On Equity |